Giuseppe Curigliano, MD, PhD, Professor at University of Milan and Head of Phase I Division at IEO, ESMO Council Member, Tweets are my own
Oct 31, 2022 • 12 tweets • 5 min read
Sponsored by @Roche,
I would like to share a Tweetorial about recent important advances in the management of advanced/metastatic triple negative breast cancer (mTNBC)
#Tweetorial#Oncology#Cancer#Diagnosis#TNBC#Immunotherapy#PDL1
TNBC is a challenging disease to treat due to its aggressive behavior, heterogeneity, and the lack of universal actionable targets. mTNBC is commonly diagnosed at a younger age than other BC subtypes and its prognosis is poor, with a median survival of <2 years.